Publications by authors named "P S Mangat"
Article Synopsis
- The study evaluated the effectiveness of palbociclib, a targeted cancer therapy, in patients with advanced cancer exhibiting specific genomic alterations, focusing on two patient groups: those with head and neck cancer (HNC) and those with a mix of histologies (HP).
- Results showed that 40% of the HNC patients achieved disease control, which was statistically significant, while only 13% of the HP cohort did, failing to meet the criteria for significance.
- The treatment had notable side effects, with over 40% of patients experiencing serious adverse events, primarily blood-related issues like neutropenia and thrombocytopenia.
Purpose: Targeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with soft tissue sarcoma with cyclin-dependent kinase 4 () amplification treated with palbociclib are reported.
Methods: Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0 to 2, adequate organ function, and no standard treatment options.
Landraces are an important reservoir of genetic variation that can expand the narrow genetic base of cultivated cotton. In this study, quantitative trait loci (QTL) analysis was conducted using an F population developed from crosses between the landrace Hopi and inbred TM-1. A high-density genetic map spanning 2253.
View Article and Find Full Text PDFPurpose: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with various solid tumors with germline or somatic mutations treated with talazoparib are reported.
Methods: Eligible patients had advanced solid tumors, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options.
Article Synopsis
- The study evaluates the effectiveness of targeted agents, specifically pertuzumab plus trastuzumab, in patients with advanced biliary tract cancer (BTC) who have specific genomic alterations.
- Out of 29 enrolled patients, the treatment showed a 40% disease control rate, with some experiencing significant responses, indicating potential benefits of this combination therapy.
- Although the treatment was generally well-received, a few patients reported notable adverse events, highlighting the importance of monitoring safety alongside treatment efficacy.